Nucleus Software Exports Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/njechszp8oswk6jk08tbdg9w.pdf

Key Takeaways


Financial Performance

Dusad: "As you would have noticed, we have had a fall in our top line as well as bottom line. I would like to highlight to you that we do not give excessive weightage to quarterly or for that matter, yearly numbers. We are focused on building a long-term enterprise and hence, we would allow such things to happen to ensure that our customers get the services, is retained and the best talent is further attracted."

The Hoshin Kanri Investment

Bhise: "This is called Hoshin Kanri, based on Toyota Production System Principles. This is to bring in continuous and long term improvements in all areas of our work for the ultimate objective of significantly enhancing our end customer experience."

Customer Dynamics and Repricing

Bhise: "We cannot let you know the time it will take."

Order Book and Pipeline


Geographic and Product Developments


Guidance and Commitments

CommitmentSpecificsTimeline
Margin improvementConfident of improving from Q1 FY25 levels, no number givenNo timeline stated
International revenue growthGrowth will start happening in Southeast Asia, Middle East, Australia"Coming quarters"
New customer additionsHopes to start adding value to new customers as lead times and pricing complexity are reducedNo timeline stated
Sales leadership hiresPlans to onboard sales leaders in different regionsNo timeline stated
Hoshin Kanri updatesMore updates will be shared going forwardNo timeline stated
Investment benefit clarityExact reasons for slower-than-expected revenue acceleration may be shared"Next quarter"

Key Metrics

MetricQ1 FY25
Consolidated revenue₹195.4 cr, against ₹210.3 cr QoQ and ₹206.8 cr YoY
Product revenue₹168 cr, against ₹179.4 cr QoQ and ₹182.6 cr YoY
Projects and services revenue₹27.4 cr, against ₹30.9 cr QoQ and ₹24.2 cr YoY
EBITDA₹28.8 cr (14.7% of revenue), against ₹58 cr (27.6%) QoQ and ₹62.3 cr (30.1%) YoY
EBITDA margin14.7%, against 27.6% QoQ and 30.1% YoY
Net profit₹30.2 cr (15.5% of revenue), against ₹52.1 cr (24.8%) QoQ and ₹53.6 cr (25.9%) YoY
EPS₹11.28, against ₹19.48 QoQ and ₹20 YoY
Cost of delivery (incl. product development)75.5% of revenue, against 63.5% QoQ and 60.5% YoY
Domestic revenue share58% of total revenue, against 48% in Q1 FY24
International revenue share42% of total revenue, against 52% in Q1 FY24
Order book₹813.4 cr (₹752.2 cr product, ₹61.2 cr projects and services), against ₹780 cr as on Mar 31, 2024
Total cash and cash equivalents₹920.8 cr, against ₹808 cr as on Mar 31, 2024
Revenue from top five clients28.8% of revenue, against 27.5% QoQ
Headcount addition62 Nucleics added during the quarter
New customer revenueNil, entire revenue from existing customers